Obesity: Next game changer of allergic airway diseases?

Abstract

Obesity and allergic diseases are global health concerns, both of which are seeing an increase in prevalence in recent years. Obesity has been recognised as an important comorbidity in subpopulations with allergic airway diseases, which represents a unique phenotype and endotype. Obesity-related allergic airway diseases are associated with exacerbated clinical symptom burden, altered immune response, increased disease severity and compromised predictive capability of conventional biomarkers for evaluating endotype and prognosis. Moreover, treatment of obesity-related allergic airway diseases is challenging because this unique endotype and phenotype is associated with poor response to standard therapeutic strategies. Therapeutic regimen that involves weight loss by non-surgical and surgical interventions, gut microbiome-targeted treatment, glucagon-like peptide-1 receptor agonist and other agents should be considered in this population. In this review, we outline the current knowledge of the impact of obesity on prevalence, endotypes, clinical symptom and management of allergic airway diseases. Increased understanding of the implications of obesity may contribute to better treatment options for the obesity-related refractory airway inflammation, particularly in precision medicine.

Keywords

allergic airway diseases / biologics / endotype / obesity / therapeutic resistance

References

[1] Gonzalez-Muniesa P, Martinez-Gonzalez MA, Hu FB, et al. Obesity. Nat Rev Dis Primers. 2017; 3: 17034.

[2] Geissler N, Orola M, Alinaghi M, et al. Obesity increases allergic airway inflammation that can be successfully treated by oral tolerance. Allergy. 2024; 79(2): 529-533.

[3] Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008; 8(3): 218-230.

[4] Chen W, Bai Y, Fang P, et al. Body mass indexaeuros effect on CRSwNP extends to pathological endotype and recurrence. Rhinology. 2024; 62(3): 370-382.

[5] Bapat SP, Whitty C, Mowery CT, et al. Obesity alters pathology and treatment response in inflammatory disease. Nature. 2022; 604(7905): 337-342.

[6] Lugogo N, Green CL, Agada N, et al. Obesity's effect on asthma extends to diagnostic criteria. J Allergy Clin Immunol. 2018; 141(3): 1096-1104.

[7] Huang J, Huffman JE, Huang Y, et al. Genomics and phenomics of body mass index reveals a complex disease network. Nat Commun. 2022; 13(1): 7973.

[8] Paciencia I, Cavaleiro Rufo J, Silva D, et al. Exposure to indoor endocrine-disrupting chemicals and childhood asthma and obesity. Allergy. 2019; 74(7): 1277-1291.

[9] Wood LG, Li Q, Scott HA, et al. Saturated fatty acids, obesity, and the nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome in asthmatic patients. J Allergy Clin Immunol. 2019; 143(1): 305-315.

[10] Tashiro H, Shore SA. The gut microbiome and ozone-induced airway hyperresponsiveness. mechanisms and therapeutic prospects. Am J Respir Cell Mol Biol. 2021; 64(3): 283-291.

[11] Parasuaraman G, Ayyasamy L, Aune D, et al. The association between body mass index, abdominal fatness, and weight change and the risk of adult asthma: a systematic review and meta-analysis of cohort studies. Sci Rep. 2023; 13(1): 7745.

[12] Bhattacharyya N. Associations between obesity and inflammatory sinonasal disorders. Laryngoscope. 2013; 123(8): 1840-1844.

[13] Luo X, Xiang J, Dong X, et al. Association between obesity and atopic disorders in Chinese adults: an individually matched case-control study. BMC Public Health. 2013; 13: 12.

[14] Hoying D, Miller K, Tanzo J, et al. Evaluating the association of obesity and chronic rhinosinusitis: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2024; 170(3): 708-723.

[15] Nam JS, Roh YH, Fahad WA, et al. Association between obesity and chronic rhinosinusitis with nasal polyps: a national population-based study. BMJ Open. 2021; 11(5): e047230.

[16] Zhou J, Luo F, Han Y, Lou H, Tang X, Zhang L. Obesity/overweight and risk of allergic rhinitis: a meta-analysis of observational studies. Allergy. 2020; 75(5): 1272-1275.

[17] Abramson MJ, Schindler C, Schikowski T, et al. Rhinitis in Swiss adults is associated with asthma and early life factors, but not second hand tobacco smoke or obesity. Allergol Int. 2016; 65(2): 192-198.

[18] Han YY, Forno E, Gogna M, Celedon JC. Obesity and rhinitis in a nationwide study of children and adults in the United States. J Allergy Clin Immunol. 2016; 137(5): 1460-1465.

[19] Malden S, Gillespie J, Hughes A, et al. Obesity in young children and its relationship with diagnosis of asthma, vitamin D deficiency, iron deficiency, specific allergies and flat-footedness: a systematic review and meta-analysis. Obes Rev. 2021; 22(3): e13129.

[20] Deng X, Ma J, Yuan Y, Zhang Z, Niu W. Association between overweight or obesity and the risk for childhood asthma and wheeze: an updated meta-analysis on 18 articles and 73 252 children. Pediatr Obes. 2019; 14(9): e12532.

[21] Sidell D, Shapiro NL, Bhattacharyya N. Obesity and the risk of chronic rhinosinusitis, allergic rhinitis, and acute otitis media in school-age children. Laryngoscope. 2013; 123(10): 2360-2363.

[22] Yu H, Chen L, Zhang Y. Maternal prepregnancy body mass index, gestational weight gain, and allergic diseases in children: a systematic review and meta-analysis. Obes Rev. 2024; 25(2): e13653.

[23] Mubanga M, Brew BH, Karim H, et al. Maternal body mass index in pregnancy and offspring asthma and food allergy. Allergy. 2023; 78(9): 2556-2558.

[24] Chen Y, Zhu J, Lyu J, et al. Association of maternal prepregnancy weight and gestational weight gain with children's allergic diseases. JAMA Netw Open. 2020; 3(9): e2015643.

[25] Rastogi S, Rastogi D. The epidemiology and mechanisms of lifetime cardiopulmonary morbidities associated with pre-pregnancy obesity and excessive gestational weight gain. Front Cardiovasc Med. 2022; 9: 844905.

[26] Ogulur I, Mitamura Y, Yazici D, et al. Type 2 immunity in allergic diseases. Cell Mol Immunol. 2025; 22(3): 211-242.

[27] Desai D, Newby C, Symon FA, et al. Elevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthma. Am J Respir Crit Care Med. 2013; 188(6): 657-663.

[28] Grotta MB, Squebola-Cola DM, Toro AA, et al. Obesity increases eosinophil activity in asthmatic children and adolescents. BMC Pulm Med. 2013; 13: 39.

[29] Farahi N, Loutsios C, Tregay N, et al. In vivo imaging reveals increased eosinophil uptake in the lungs of obese asthmatic patients. J Allergy Clin Immunol. 2018; 142(5): 1659-1662.e1658.

[30] Ying X, Lin J, Yuan S, et al. Comparison of pulmonary function and inflammation in children/adolescents with new-onset asthma with different adiposity statuses. Nutrients. 2022; 14(14): 2968.

[31] Zheng H, Zhang X, Castillo EF, Luo Y, Liu M, Yang XO. Leptin enhances TH2 and ILC2 responses in allergic airway disease. J Biol Chem. 2016; 291(42): 22043-22052.

[32] Wang X, Shen Y, Ke X, Kang H, Hong S. Role of leptin/ILC2 axis in allergic rhinitis in obese children. Int J Pediatr Otorhinolaryngol. 2022; 157: 111127.

[33] Kato A, Schleimer RP, Bleier BS. Mechanisms and pathogenesis of chronic rhinosinusitis. J Allergy Clin Immunol. 2022; 149(5): 1491-1503.

[34] Chaaban MR, Asosingh K, Comhair S, Hoying D. Assessing the clinico-immunological profile of patients with obesity and chronic rhinosinusitis. Int Forum Allergy Rhinol. 2024; 14(6): 1036-1045.

[35] Chen JH, Qin L, Shi YY, et al. IL-17 protein levels in both induced sputum and plasma are increased in stable but not acute asthma individuals with obesity. Respir Med. 2016; 121: 48-58.

[36] Scott HA, Ng SH, McLoughlin RF, et al. Effect of obesity on airway and systemic inflammation in adults with asthma: a systematic review and meta-analysis. Thorax. 2023; 78(10): 957-965.

[37] Leija-Martinez JJ, Del-Rio-Navarro BE, Sanchez-Munoz F, et al. Associations of TNFA, IL17A, and RORC mRNA expression levels in peripheral blood leukocytes with obesity-related asthma in adolescents. Clin Immunol. 2021; 229: 108715.

[38] Baltieri L, Cazzo E, Oliveira Modena DA, Gobato Rentel RC, Martins LC, Chaim EA. Correlation between levels of adipokines and inflammatory mediators with spirometric parameters in individuals with obesity and symptoms of asthma: cross-sectional study. Pulmonology. 2022; 28(2): 105-112.

[39] Akar-Ghibril N, Greco KF, Jackson-Browne M, Phipatanakul W, Permaul P. High plasma IL-6 levels may enhance the adverse effects of mouse allergen exposure in urban schools on asthma morbidity in children. J Allergy Clin Immunol. 2023; 152(6): 1677-1682.

[40] Zheng J, Zhang X, Zhang L, Zhang HP, Wang L, Wang G. Interactive effects between obesity and atopy on inflammation: a pilot study for asthma phenotypic overlap. Ann Allergy Asthma Immunol. 2016; 117(6): 716-717.

[41] Kim HY, Lee HJ, Chang YJ, et al. Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat Med. 2014; 20(1): 54-61.

[42] Dooley AA, Pillai DK. Paediatric obesity-related asthma: disease burden and effects on pulmonary physiology. Paediatr Respir Rev. 2021; 37: 15-17.

[43] Kanno T, Nakajima T, Miyako K, Endo Y. Lipid metabolism in Th17 cell function. Pharmacol Ther. 2023; 245: 108411.

[44] Endo Y, Asou HK, Matsugae N, et al. Obesity drives Th17 cell differentiation by inducing the lipid metabolic kinase, ACC1. Cell Rep. 2015; 12(6): 1042-1055.

[45] Vollmer CM, Dias ASO, Lopes LM, et al. Leptin favors Th17/Treg cell subsets imbalance associated with allergic asthma severity. Clin Transl Allergy. 2022; 12(6): e12153.

[46] Han MW, Kim SH, Oh I, Kim YH, Lee J. Obesity can contribute to severe persistent allergic rhinitis in children through leptin and interleukin-1beta. Int Arch Allergy Immunol. 2021; 182(6): 546-552.

[47] Liu W, Zeng Q, Zhou L, Li Y, Chen Y, Luo R. Leptin/osteopontin axis contributes to enhanced T helper 17 type responses in allergic rhinitis. Pediatr Allergy Immunol. 2018; 29(6): 622-629.

[48] Gerriets VA, Danzaki K, Kishton RJ, et al. Leptin directly promotes T-cell glycolytic metabolism to drive effector T-cell differentiation in a mouse model of autoimmunity. Eur J Immunol. 2016; 46(8): 1970-1983.

[49] Yu Y, Liu Y, Shi FD, Zou H, Matarese G, La Cava A. Cutting edge: leptin-induced RORgammat expression in CD4+ T cells promotes Th17 responses in systemic lupus erythematosus. J Immunol. 2013; 190(7): 3054-3058.

[50] Watanabe K, Suzukawa M, Arakawa S, et al. Leptin enhances cytokine/chemokine production by normal lung fibroblasts by binding to leptin receptor. Allergol Int. 2019; 68S: S3-S8.

[51] Chong L, Li H, Zhu L, Yu G. Regulatory effect of mitoQ on the mtROS-NLRP3 inflammasome pathway in leptin-pretreated BEAS-2 cells. Exp Ther Med. 2021; 21(5): 466.

[52] Zhu L, Chen X, Chong L, et al. Adiponectin alleviates exacerbation of airway inflammation and oxidative stress in obesity-related asthma mice partly through AMPK signaling pathway. Int Immunopharmacol. 2019; 67: 396-407.

[53] Samaha MM, El-Desoky MM, Hisham FA. AdipoRon, an adiponectin receptor agonist, modulates AMPK signaling pathway and alleviates ovalbumin-induced airway inflammation in a murine model of asthma. Int Immunopharmacol. 2024; 136: 112395.

[54] Otelea MR, Arghir OC, Zugravu C, Rascu A. Adiponectin and asthma: knowns, unknowns and controversies. Int J Mol Sci. 2021; 22(16): 8971.

[55] Nyambuya TM, Dludla PV, Mxinwa V, Nkambule BB. Obesity-related asthma in children is characterized by T-helper 1 rather than T-helper 2 immune response: a meta-analysis. Ann Allergy Asthma Immunol. 2020; 125(4): 425-432.e424.

[56] Liu W, Zeng Q, Zhou L, Luo R, Dong H. Association of leptin with disease severity and inflammation indicators in Chinese obese children with allergic rhinitis. Pediatr Allergy Immunol. 2018; 29(2): 186-193.

[57] Aziz DA, Bajwa RA, Viquar W, Siddiqui F, Abbas A. Asthma exacerbations and body mass index in children and adolescents: experience from a tertiary care center. Monaldi Arch Chest Dis. 2023; 94(2).

[58] Ilmarinen P, Pardo A, Tuomisto LE, et al. Long-term prognosis of new adult-onset asthma in obese patients. Eur Respir J. 2021; 57(4): 2001209.

[59] Forno E, Han YY, Mullen J, Celedon JC. Overweight, obesity, and lung function in children and adults—a meta-analysis. J Allergy Clin Immunol Pract. 2018; 6(2): 570-581.e510.

[60] Forno E, Weiner DJ, Mullen J, et al. Obesity and airway dysanapsis in children with and without asthma. Am J Respir Crit Care Med. 2017; 195(3): 314-323.

[61] Chen F, Liu Y, Sun LH, Zeng Z, Huang X. Effect of overweight/obesity on relationship between fractional exhaled nitric oxide and airway hyperresponsiveness in Chinese elderly patients with asthma. Int J Immunopathol Pharmacol. 2024; 38: 3946320241246713.

[62] Yao TC, Tsai HJ, Chang SW, et al. Obesity disproportionately impacts lung volumes, airflow and exhaled nitric oxide in children. PLoS One. 2017; 12(4): e0174691.

[63] Liu Y, Zheng J, Zhang HP, et al. Obesity-associated metabolic signatures correlate to clinical and inflammatory profiles of asthma: a pilot study. Allergy Asthma Immunol Res. 2018; 10(6): 628-647.

[64] Ciprandi G, Ricciardolo FLM, Signori A, et al. Increased body mass index and bronchial impairment in allergic rhinitis. Am J Rhinol Allergy. 2013; 27(6): 195-201.

[65] Burgess JA, Matheson MC, Diao F, et al. Bronchial hyperresponsiveness and obesity in middle age: insights from an Australian cohort. Eur Respir J. 2017; 50(3): 1602181.

[66] Orfanos S, Jude J, Deeney BT, et al. Obesity increases airway smooth muscle responses to contractile agonists. Am J Physiol Lung Cell Mol Physiol. 2018; 315(5): L673-L681.

[67] Bourdin A, Bommart S, Marin G, et al. Obesity in women with asthma: baseline disadvantage plus greater small-airway responsiveness. Allergy. 2023; 78(3): 780-790.

[68] Zhang C, Qu Q, Pan K. Analysis of disease burden due to high body mass index in childhood asthma in China and the USA based on the Global Burden of Disease Study 2019. PLoS One. 2023; 18(3): e0283624.

[69] Luthe SK, Hirayama A, Goto T, Faridi MK, Camargo CA, Hasegawa K. Association between obesity and acute severity among patients hospitalized for asthma exacerbation. J Allergy Clin Immunol Pract. 2018; 6(6): 1936-1941.e1934.

[70] Gross E, Lee DS, Hotz A, Ngo KC, Rastogi D. Impact of obesity on asthma morbidity during a hospitalization. Hosp Pediatr. 2018; 8(9): 538-546.

[71] Schatz M, Zeiger RS, Yang SJ, et al. Prospective study on the relationship of obesity to asthma impairment and risk. J Allergy Clin Immunol Pract. 2015; 3(4): 560-565.e561.

[72] Das J, Andrews C, Flenady V, Clifton VL. Maternal asthma during pregnancy and extremes of body mass index increase the risk of perinatal mortality: a retrospective cohort study. J Asthma. 2022; 59(10): 2108-2116.

[73] Visness CM, London SJ, Daniels JL, et al. Association of childhood obesity with atopic and nonatopic asthma: results from the National Health and Nutrition Examination Survey 1999-2006. J Asthma. 2010; 47(7): 822-829.

[74] Forno E, Acosta-Perez E, Brehm JM, et al. Obesity and adiposity indicators, asthma, and atopy in Puerto Rican children. J Allergy Clin Immunol. 2014; 133(5): 1308-1314. 1314 e1301-1305.

[75] Xu Y, Cao M, Yang W, Zhao Y. Snoring in patients with chronic rhinosinusitis after endoscopic sinus surgery. Sleep Breath. 2024; 28(2): 895-904.

[76] Xie S, Jiang S, Fan R, et al. Elevated body mass index increased the risk of recurrence in Chinese patients with chronic rhinosinusitis. Am J Otolaryngol. 2023; 44(4): 103841.

[77] Lu KD, Breysse PN, Diette GB, et al. Being overweight increases susceptibility to indoor pollutants among urban children with asthma. J Allergy Clin Immunol. 2013; 131(4): 1017-1023. 1023 e1011-1013.

[78] Permaul P, Gaffin JM, Petty CR, et al. Obesity may enhance the adverse effects of NO(2) exposure in urban schools on asthma symptoms in children. J Allergy Clin Immunol. 2020; 146(4): 813-820.e812.

[79] Wu TD, Brigham EP, Peng R, et al. Overweight/obesity enhances associations between secondhand smoke exposure and asthma morbidity in children. J Allergy Clin Immunol Pract. 2018; 6(6): 2157-2159.e2155.

[80] Li RL, Wu CT, Chen SM, et al. Allergic rhinitis children with obesity are more vulnerable to air pollution: a cross sectional study. Sci Rep. 2023; 13(1): 3658.

[81] Stubbs MA, Clark VL, Gibson PG, Yorke J, McDonald VM. Associations of symptoms of anxiety and depression with health-status, asthma control, dyspnoea, dysfunction breathing and obesity in people with severe asthma. Respir Res. 2022; 23(1): 341.

[82] Sastre J, Crespo A, Fernandez-Sanchez A, Rial M, Plaza V, investigators of the CSG. Anxiety, depression, and asthma control: changes after standardized treatment. J Allergy Clin Immunol Pract. 2018; 6(6): 1953-1959.

[83] Sutherland ER, Lehman EB, Teodorescu M, Wechsler ME, National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Body mass index and phenotype in subjects with mild-to-moderate persistent asthma. J Allergy Clin Immunol. 2009; 123(6): 1328-1334.e1321.

[84] Anderson WJ, Lipworth BJ. Does body mass index influence responsiveness to inhaled corticosteroids in persistent asthma?. Ann Allergy Asthma Immunol. 2012; 108(4): 237-242.

[85] Thompson CA, Eslick SR, Berthon BS, Wood LG. Asthma medication use in obese and healthy weight asthma: systematic review/meta-analysis. Eur Respir J. 2021; 57(3): 220039.

[86] Forno E, Lescher R, Strunk R, et al. Decreased response to inhaled steroids in overweight and obese asthmatic children. J Allergy Clin Immunol. 2011; 127(3): 741-749.

[87] Boulet LP, Franssen E. Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir Med. 2007; 101(11): 2240-2247.

[88] Lang JE, Fitzpatrick AM, Mauger DT, et al. Overweight/obesity status in preschool children associates with worse asthma but robust improvement on inhaled corticosteroids. J Allergy Clin Immunol. 2018; 141(4): 1459-1467.e1452.

[89] de Sa Pittondo M, Migueis DP, Fujita RR, Thamboo A, Tepedino MS, Pezato R. Effect of body weight on response to nasal glucocorticoid treatment in allergic rhinitis. Indian J Otolaryngol Head Neck Surg. 2024; 76(1): 1002-1009.

[90] Goleva E, Covar R, Martin RJ, Leung DY. Corticosteroid pharmacokinetic abnormalities in overweight and obese corticosteroid resistant asthmatics. J Allergy Clin Immunol Pract. 2016; 4(2): 357-360.e352.

[91] Zhang Y, Shen S, Liu Y, et al. The influence of body mass index on glucocorticoid insensitivity in chronic rhinosinusitis with nasal polyps. J Pers Med. 2022; 12(11): 1935.

[92] McGarry ME, Castellanos E, Thakur N, et al. Obesity and bronchodilator response in black and Hispanic children and adolescents with asthma. Chest. 2015; 147(6): 1591-1598.

[93] Gibson PG, Reddel H, McDonald VM, et al. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. Intern Med J. 2016; 46(9): 1054-1062.

[94] Sposato B, Scalese M, Milanese M, et al. Factors reducing omalizumab response in severe asthma. Eur J Intern Med. 2018; 52: 78-85.

[95] Oliveira MJ, Vieira M, Coutinho D, et al. Severe asthma in obese patients: improvement of lung function after treatment with omalizumab. Pulmonology. 2019; 25(1): 15-20.

[96] Geng B, Dixon AE, Ko J, et al. Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol. 2022; 128(5): 553-560.

[97] FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018; 6(1): 51-64.

[98] Al-Ahmad M, Ali A, Maher A. Factors influencing poor response to type 2 targeted therapies in severe asthma: a retrospective cohort study. BMC Pulm Med. 2023; 23(1): 490.

[99] Trudo F, Hirsch I, Martin U. Impact of body mass index on efficacy of benralizumab in patients with severe, uncontrolled eosinophilic asthma: pooled analysis of the SIROCCO and CALIMA Trials. Pneumologie. 2019; 73(S 01): P246.

[100] Bachert C, Han JK, Desrosiers MY, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022; 149(4): 1309-1317.e1312.

[101] Bagnasco D, Bondi B, Caminati M, et al. Evaluation of clinical remission in best-performing severe asthmatic patients treated for three years with mepolizumab. Biomedicines. 2024; 12(5): 960.

[102] Thomas D, McDonald VM, Stevens S, et al. Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients. Allergy. 2024; 79(2): 384-392.

[103] Reilly C, Raja A, Anilkumar P, et al. The clinical effectiveness of mepolizumab treatment in severe eosinophilic asthma; outcomes from four years cohort evaluation. J Asthma. 2024; 61(6): 561-573.

[104] Albers FC, Papi A, Taille C, et al. Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA. Respir Res. 2019; 20(1): 169.

[105] Da Cunha Fonseca A, Machado D, Pascoal I, Franco I, Lima R. Severe asthma in obese patients: what to expect with mepolizumab?. European Respiratory Journal. 2022; 60(suppl 66): 3216.

[106] Busse WW, Paggiaro P, Munoz X, et al. Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma. Eur Respir J. 2021; 58(4): 2004605.

[107] Quarato CMI, Tondo P, Lacedonia D, et al. Clinical remission in patients affected by severe eosinophilic asthma on dupilumab therapy: a long-term real-life study. J Clin Med. 2024; 13(1): 291.

[108] Cho S, Tan B, Cohen N, et al. Dupilumab improves objective, subjective, and health-related quality of life outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP), regardless of BMI ≥30 kg/m2 or weight ≥90 kg: post-hoc analysis of the SINUS-24 and SINUS-52 studies. Journal of Allergy and Clinical Immunology. 2022; 149(2): AB143. Supplement.

[109] Yonekura S, Okamoto Y, Sakurai D, et al. An analysis of factors related to the effect of sublingual immunotherapy on Japanese cedar pollen induced allergic rhinitis. Allergol Int. 2018; 67(2): 201-208.

[110] Li Y, Xiao H, Zeng Y, Tang Y, Zhou L, Liu W. Baseline severity and disease duration can predict the response to allergen-specific immunotherapy in allergic rhinitis. Iran J Allergy Asthma Immunol. 2024; 23(1): 52-58.

[111] Kuriakose R, Kohn N, Farzan S. The effectiveness of immunotherapy for allergic asthma among different weight categories. Journal of Allergy and Clinical Immunology. 2018; 141(2): AB273. Supplement 1.

[112] Yang Y, Ma D, Huang N, et al. Safety of house dust mite subcutaneous immunotherapy in preschool children with respiratory allergic diseases. Ital J Pediatr. 2021; 47(1): 101.

[113] Liu Z, Lu H, Feng X, Hu L, Wang J, Yu H. Predictive methods for efficacy of house dust mite subcutaneous immunotherapy in allergic rhinitis patients: a prospective study in a Chinese population. Int Forum Allergy Rhinol. 2020; 10(3): 314-319.

[114] Steele TO, Mace JC, DeConde AS, et al. Does comorbid obesity impact quality of life outcomes in patients undergoing endoscopic sinus surgery?. Int Forum Allergy Rhinol. 2015; 5(12): 1085-1094.

[115] Wardlow RD, Bernstein IA, Orlov CP, Rowan NR. Implications of obesity on endoscopic sinus surgery postoperative complications: an analysis of the NSQIP database. Otolaryngol Head Neck Surg. 2021; 164(3): 675-682.

[116] Langton D, Wang W, Sha J, et al. Predicting the response to bronchial thermoplasty. J Allergy Clin Immunol Pract. 2020; 8(4): 1253-1260.e1252.

[117] Chupp G, Kline JN, Khatri SB, et al. Bronchial thermoplasty in patients with severe asthma at 5 years: the Post-FDA approval clinical trial evaluating bronchial thermoplasty in severe persistent asthma study. Chest. 2022; 161(3): 614-628.

[118] Nishi K, Yoshimura C, Morita K, et al. Effectiveness of bronchial thermoplasty in patients with asthma exhibiting overweight/obesity and low quality of life. World Allergy Organ J. 2023; 16(3): 100756.

[119] Telenga ED, Tideman SW, Kerstjens HA, et al. Obesity in asthma: more neutrophilic inflammation as a possible explanation for a reduced treatment response. Allergy. 2012; 67(8): 1060-1068.

[120] Diaz J, Warren L, Helfner L, et al. Obesity shifts house dust mite-induced airway cellular infiltration from eosinophils to macrophages: effects of glucocorticoid treatment. Immunol Res. 2015; 63(1-3): 197-208.

[121] Reyes-Angel J, Kaviany P, Rastogi D, Forno E. Obesity-related asthma in children and adolescents. Lancet Child Adolesc Health. 2022; 6(10): 713-724.

[122] Panda L, Gheware A, Rehman R, et al. Linoleic acid metabolite leads to steroid resistant asthma features partially through NF-kappaB. Sci Rep. 2017; 7(1): 9565.

[123] Bantula M, Tubita V, Roca-Ferrer J, et al. Weight loss and vitamin D improve hyporesponsiveness to corticosteroids in obese asthma. J Investig Allergol Clin Immunol. 2023; 33(6): 464-473.

[124] Sullivan PW, Ghushchyan VH, Globe G, Schatz M. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol. 2018; 141(1): 110-116.e117.

[125] Han J, Nguyen J, Kim Y, et al. Effect of inhaled corticosteroid use on weight (BMI) in pediatric patients with moderate-severe asthma. J Asthma. 2019; 56(3): 263-269.

[126] Hirsch AG, Yan XS, Sundaresan AS, et al. Five-year risk of incident disease following a diagnosis of chronic rhinosinusitis. Allergy. 2015; 70(12): 1613-1621.

[127] Shamji MH, Palmer E, Layhadi JA, Moraes TJ, Eiwegger T. Biological treatment in allergic disease. Allergy. 2021; 76(9): 2934-2937.

[128] Pilkington AW, Buragamadagu B, Johnston RA. Weighted breaths: exploring biologic and non-biologic therapies for co-existing asthma and obesity. Curr Allergy Asthma Rep. 2024; 24(7): 381-393.

[129] Ediger D, Gunaydin FE, Erbay M, Pekbak G. Can omalizumab be an alternative treatment for non-atopic severe asthma? A real-life experience with omalizumab. Tuberk Toraks. 2023; 71(1): 24-33.

[130] Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021; 9(10): 1141-1153.

[131] Lipworth BJ, Han JK, Desrosiers M, et al. Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps. N Engl J Med. 2025; 392(12): 1178-1188.

[132] Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013; 188(11): 1294-1302.

[133] Ahmad S, Mohd Noor N, Engku Nur Syafirah EAR, et al. Anti-tumor necrosis factor for supplementary management in severe asthma: a systematic review and meta-analysis. J Interferon Cytokine Res. 2023; 43(2): 77-85.

[134] Mahar PD, Zubrinich CM, Manuelpillai N, Foley P. Combination treatment with monoclonal antibodies: secukinumab, benralizumab and dupilumab for the combined management of psoriasis and severe asthma. Australas J Dermatol. 2021; 62(4): 506-508.

[135] Durham SR, Shamji MH. Allergen immunotherapy: past, present and future. Nat Rev Immunol. 2023; 23(5): 317-328.

[136] Kong W, Wu Q, Zhang H, Zhang Y, Yang Q. Novel insights into central compartment atopic disease—a literature review. Expert Rev Clin Immunol. 2023; 19(8): 847-856.

[137] Russell RJ, Brightling CE. Bronchial thermoplasty: what we know, what we don't know, and what we need to know. Eur Respir J. 2022; 59(1): 2102018.

[138] Sharma V, Ricketts HC, McCombie L, et al. A total diet replacement weight management program for difficult-to-treat asthma associated with obesity: a randomized controlled feasibility trial. Chest. 2023; 163(5): 1026-1037.

[139] Freitas PD, Ferreira PG, Silva AG, et al. The role of exercise in a weight-loss program on clinical control in obese adults with asthma. a randomized controlled trial. Am J Respir Crit Care Med. 2017; 195(1): 32-42.

[140] Turk Y, Theel W, van Huisstede A, et al. Short-term and long-term effect of a high-intensity pulmonary rehabilitation programme in obese patients with asthma: a randomised controlled trial. Eur Respir J. 2020; 56(1): 1901820.

[141] Dixon AE, Pratley RE, Forgione PM, et al. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J Allergy Clin Immunol. 2011; 128(3): 508-515. e501-502.

[142] van Huisstede A, Rudolphus A, Castro Cabezas M, et al. Effect of bariatric surgery on asthma control, lung function and bronchial and systemic inflammation in morbidly obese subjects with asthma. Thorax. 2015; 70(7): 659-667.

[143] Boulet LP, Turcotte H, Martin J, Poirier P. Effect of bariatric surgery on airway response and lung function in obese subjects with asthma. Respir Med. 2012; 106(5): 651-660.

[144] Maniscalco M, Zamparelli AS, Vitale DF, et al. Long-term effect of weight loss induced by bariatric surgery on asthma control and health related quality of life in asthmatic patients with severe obesity: a pilot study. Respir Med. 2017; 130: 69-74.

[145] Michalovich D, Rodriguez-Perez N, Smolinska S, et al. Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients. Nat Commun. 2019; 10(1): 5711.

[146] Tashiro H, Cho Y, Kasahara DI, et al. Microbiota contribute to obesity-related increases in the pulmonary response to ozone. Am J Respir Cell Mol Biol. 2019; 61(6): 702-712.

[147] Toki S, Newcomb DC, Printz RL, et al. Glucagon-like peptide-1 receptor agonist inhibits aeroallergen-induced activation of ILC2 and neutrophilic airway inflammation in obese mice. Allergy. 2021; 76(11): 3433-3445.

[148] Foer D, Beeler PE, Cui J, Karlson EW, Bates DW, Cahill KN. Asthma exacerbations in patients with type 2 diabetes and asthma on glucagon-like peptide-1 receptor agonists. Am J Respir Crit Care Med. 2021; 203(7): 831-840.

[149] Holguin F, Grasemann H, Sharma S, et al. L-Citrulline increases nitric oxide and improves control in obese asthmatics. JCI Insight. 2019; 4(24): e131733.

[150] O'Sullivan B, Ounpraseuth S, James L, et al. Vitamin D oral replacement in children with obesity related asthma: vDORA1 randomized clinical trial. Clin Pharmacol Ther. 2024; 115(2): 231-238.

[151] Denisenko Y, Novgorodtseva T, Antonyuk M, et al. 1-O-alkyl-glycerols from squid berryteuthis magister reduce inflammation and modify fatty acid and plasmalogen metabolism in asthma associated with obesity. Mar Drugs. 2023; 21(6): 351.

[152] Chandrasekaran R, Bruno SR, Mark ZF, et al. Mitoquinone mesylate attenuates pathological features of lean and obese allergic asthma in mice. Am J Physiol Lung Cell Mol Physiol. 2023; 324(2): L141-L153.

[153] Xu S, Wang N, Yan D, Zhong Y. Platycoside E alleviates allergic airway inflammation in obesity-related asthma mouse model. Mol Immunol. 2023; 162: 74-83.

[154] Tashiro H, Kurihara Y, Kuwahara Y, Takahashi K. Impact of obesity in asthma: possible future therapies. Allergol Int. 2024; 73(1): 48-57.

[155] Shah R, Davitkov P, Abu Dayyeh BK, Saumoy M, Murad MH. AGA technical review on intragastric balloons in the management of obesity. Gastroenterology. 2021; 160(5): 1811-1830.

[156] Hossain N, Arhi C, Borg CM. Is bariatric surgery better than nonsurgical weight loss for improving asthma control? a systematic review. Obes Surg. 2021; 31(4): 1810-1832.

[157] Strati F, Lattanzi G, Amoroso C, Facciotti F. Microbiota-targeted therapies in inflammation resolution. Semin Immunol. 2022; 59: 101599.

[158] Palmisano S, Campisciano G, Silvestri M, et al. Changes in gut microbiota composition after bariatric surgery: a new balance to decode. J Gastrointest Surg. 2020; 24(8): 1736-1746.

[159] Kusminski CM, Perez-Tilve D, Muller TD, DiMarchi RD, Tschop MH, Scherer PE. Transforming obesity: the advancement of multi-receptor drugs. Cell. 2024; 187(15): 3829-3853.

[160] Sung M. Trends of vitamin D in asthma in the pediatric population for two decades: a systematic review. Clin Exp Pediatr. 2023; 66(8): 339-347.

[161] Chen Z, Salam MT, Alderete TL, et al. Effects of childhood asthma on the development of obesity among school-aged children. Am J Respir Crit Care Med. 2017; 195(9): 1181-1188.

[162] Contreras ZA, Chen Z, Roumeliotaki T, et al. Does early onset asthma increase childhood obesity risk? A pooled analysis of 16 European cohorts. Eur Respir J. 2018; 52(3): 1800504.

[163] Stratakis N, Garcia E, Chandran A, et al. The Role of childhood asthma in obesity development: a nationwide US multicohort study. Epidemiology. 2022; 33(1): 131-140.

[164] Moitra S, Carsin AE, Abramson MJ, et al. Long-term effect of asthma on the development of obesity among adults: an international cohort study, ECRHS. Thorax. 2023; 78(2): 128-135.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.